TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GENMAB TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GENMAB Share Price
Certificat
DE000CL7HDE8
| Market Closed - Boerse Frankfurt Warrants 01:21:25 22/06/2024 am IST | ||
| 2.1 EUR | +5.53% |
|
| Current month | -49.38% | ||
| 1 month | -58.28% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 21/24/21 | 2.04 | +2.51% |
| 20/24/20 | 1.99 | +41.13% |
| 19/24/19 | 1.41 | -37.05% |
| 18/24/18 | 2.24 | +6.16% |
| 17/24/17 | 2.11 | -16.60% |
Real-time Boerse Frankfurt Warrants
Last update June 22, 2024 at 01:21 am IST
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | CL7HDE |
| ISIN | DE000CL7HDE8 |
| Date issued | 07/04/2020 |
| Strike | 1,665 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.67 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.07 € |
|---|---|
| Lowest since issue | 1.41 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,806
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.43%
- Stock Market
- Certificates
- Certificat
